Expressing of linc-223 and miR-125a in Patients with Acute Leukemia and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2020.06.005
- Author:
Ai-Fei LIU
1
;
Yi-Jian CHEN
2
Author Information
1. Department of Transfusion, The First Hospital Affiliated to Gannan Medical University, Ganzhou 341000, Jiangxi Province, China.
2. Department of Hematology, the First Hospital Affiliated to Gannan Medical University, Ganzhou 341000, Jiangxi Province, China,E-mail：chenyj2005@163.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Adult;
Humans;
Leukemia, Myeloid, Acute;
MicroRNAs;
Patients;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*
- From:
Journal of Experimental Hematology
2020;28(6):1819-1825
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the expression level of linc-223 and miR-125a in the patients with adult acute leukemia (AL) and explore the relationship between the expression level and the occurrence, development, prognosis of leukemia.
METHODS:Bone marrow samples of 93 patients with AL treated in our hospital from January 2017 to September 2017 were enrolled, including 21 cases of acute lymphoblastic leukemia (ALL) and 72 cases of acute non-lymphocytic leukemia (ANLL). At the same time, bone marrow samples from 20 cases of non-malignant hematopathy patients in the same period were enrolled as control group. Real-time quantitative PCR (qRT-PCR) was used to test the expression level of linc-223 and miR-125a in bone marrow of 93 AL patients and the relationship between the level and the occurrence, development, prognosis of leukemia was analyzed.
RESULTS:There was no significant difference in the expression of linc-223 between AL patients (ANLL and ALL) and control group (P>0.05). Moreover, there was no significant correlation between linc-223 and PML-RARα gene or the remission rate of patients after treatment. The expression of miR-125a in ANLL patients was significantly lower than those in the control group (P<0.01), but there was no significant difference between the initial treatment, recurrence and remission group (P>0.05), and also for ALL and control group (P>0.05). In the newly treatment ANLL patients, the expression level of miR-125a showed negatively correlated with LDH level and the ratio of immature cells (r=-0.454, r=-0.400), but not with sex, degree of risk, peripheral blood leukocyte count, platelet count, hemoglobin content, WT1, CRP, etc. (P>0.05). There was a positive correlation between linc-223 and miR-125a in ANLL patients (r=0.296).
CONCLUSION:No abnormal expression of linc-223 was found in the bone marrow of AL patients, but miR-125a expression shows a low level and positively correlate with the expression level of linc-223 in ANLL, which is helpful for the diagnosis.
